Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Cardium Therapeutics Inc. (Trading Symbol: CRXM) reported that it has entered into a strategic collaboration and funding arrangement with Shanxi...
Cardium Therapeutics Inc. (Ticker Symbol: CRXM) reported on the Company's strategic focus on its two advanced regenerative medicine therapeutics,...
As previously reported, Cardium Therapeutics, an advanced regenerative therapeutics company, today announced that its common stock will begin trading ...
Cardium Therapeutics (NYSE MKT: CXM) today reported on advancements of the Company's two key biologics products, its Generx® candidate for the...
Cardium Therapeutics (NYSE MKT: CXM) today provided an update on its exchange listing. As previously reported, a communication from the staff of the...
Cardium Therapeutics (NYSE MKT: CXM) today announced that Cardium's Excellagen®, a wound care product indicated for the treatment of hard to heal...
LifeAgain Insurance Solutions Inc., a wholly-owned subsidiary of Cardium Therapeutics (NYSE MKT: CXM), today announced that its BlueMetric Select...
Cardium Therapeutics (NYSE MKT: CXM) today presented its financial results for the third quarter ended September 30, 2013, and reported on recent...
Cardium Therapeutics (NYSE MKT: CXM) today announced the publication of a case study, "Serial Sharp Debridement and Formulated Collagen Gel to Treat...
Cardium Therapeutics (NYSE MKT: CXM) today released the following statement. (Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) In view...
Cardium Therapeutics (NYSE MKT: CXM) today presented its financial results for the second quarter ended June 30, 2013, and reported on recent...
Cardium Therapeutics (NYSE MKT: CXM) today reported on a research collaboration with researchers at Boston Children's Hospital, to assess the medical ...
Cardium Therapeutics (NYSE MKT: CXM) today announced that it has entered into a distribution agreement with Kasiak Holdings AG for the marketing and...
Cardium Therapeutics (NYSE MKT: CXM) today announced that it has filed a new 510(k) submission for its current FDA-cleared Excellagen® advanced wound ...
Cardium Therapeutics (NYSE MKT: CXM) today announced the completion of the second tranche of its previously described registered direct offering...
Cardium Therapeutics (NYSE MKT: CXM) announced a 1-for-20 reverse split of the Company's issued and outstanding common stock effective at the open of ...
Cardium Therapeutics (NYSE MKT: CXM) today reported the voting results of its reconvened annual meeting of stockholders held earlier today. The...
Cardium Therapeutics (NYSE MKT: CXM) held its reconvened Annual Meeting of Stockholders earlier today and has temporarily adjourned the meeting to...
Cardium Therapeutics (NYSE MKT: CXM) held its Annual Meeting of Stockholders earlier today. The proposals considered at the Annual Meeting are...
Cardium Therapeutics (NYSE MKT: CXM) announced today that Institutional Shareholder Services, Inc. ("ISS") and Glass, Lewis & Co., LLC ("Glass...
Cardium Therapeutics (NYSE MKT: CXM) today presented its financial results for the first quarter ended March 31, 2013, and reported on highlights and ...
Cardium Therapeutics (NYSE MKT: CXM) today announced a publication, "Mechanistic, Technical, and Clinical Perspectives in Therapeutic Stimulation of...
Cardium Therapeutics (NYSE MKT: CXM) today announced that the Company will present a poster demonstrating the clinical benefits of Excellagen® in...
Cardium Therapeutics (NYSE MKT: CXM) today presented highlights of financial results for fiscal year ended December 31, 2012, and other recent...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.